The central goal of the Career Enhancement Program (CEP) is to use the resources at MD Anderson to train exceptional young investigators who will reduce the morbidity and mortality from ovarian cancer through making advances in the early detection, prevention, and treatment of this disease. To achieve this goal, the SPORE CEP will provide two awards, each of $50,000 annually for two years, funded from the SPORE and matching funds from MD Anderson. The intent of each CEP award is to prepare the selected scientists to become international leaders in academic research relevant to ovarian cancer. We will achieve this by aggressive recruitment of the most promising young investigators and the institution of an individualized development plan with clinical and a laboratory mentors and a mentoring committee, formal course work, coaching in grant and paper writing, leadership training, attendance at national meetings, networking with ovarian cancer scholars and completing and publishing a translational ovarian cancer research program. During our past SPORE awards, the CEP has developed the careers of 21 young investigators. In the first year of the original grant, three postdoctoral trainees received CE awards, and of the 18 faculty members supported since 2000, all have remained in academic research and 13 are engaged predominantly in ovarian cancer research. Ten have achieved peer-reviewed funding and two additional awardees have received competitive foundation grants. The six awardees in the most recently funded cycle received one R01, one R03, two CPRIT awards, two Texas Center for Nanotechnology Grants, one Liz Tilberis Scholar Award from the Ovarian Cancer Research Fund and one Susan Poorman Blackie Ovarian Cancer grant. After entering the program, awardees have published over 500 peer-reviewed papers regarding ovarian cancer. Of the faculty awardees, five are project leaders, co-investigators, collaborators or core leaders on the current SPORE (Drs. Anil Sood, Jinsong Liu, KK Wong, Vikas Kundra, and Guang Peng). Moving forward, the CEP will be led by Dr. Anil Sood, who is an outstanding role model and most effective mentor.

Public Health Relevance

Career Enhancement Program (CEP) NARRATIVE Based on 16 years of experience in developing the careers of 21 investigators during previously-funded Ovarian SPORE grants at MD Anderson, the CEP will aggressively recruit young faculty members who want to become leaders in ovarian cancer research. We will provide two years of career development with a clinical and a laboratory mentor and a mentoring team, with an individualized career development plan that will include didactic courses, coaching in grant and manuscript writing, leadership training, attendance at national meetings, and completing and publishing a translational ovarian cancer research project. We will monitor the success of our awardees and provide long-term mentorship support and advocacy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923
Zhang, Lin; Peng, Dan; Sood, Anil K et al. (2018) Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Mol Cancer Ther 17:1816-1823
Hsieh, Hui-Ju; Zhang, Wei; Lin, Shu-Hong et al. (2018) Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun 9:3982
Villar-Prados, Alejandro; Wu, Sherry Y; Court, Karem A et al. (2018) Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther :
Fleming, Nicole D; Nick, Alpa M; Coleman, Robert L et al. (2018) Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132:545-554
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Chen, Xiuhui; Mangala, Lingegowda S; Rodriguez-Aguayo, Cristian et al. (2018) RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37:107-124
Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211
Zheng, Yiyan; Sethi, Ritika; Mangala, Lingegowda S et al. (2018) Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9:476
Berger, Ashton C; Korkut, Anil; Kanchi, Rupa S et al. (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705.e9

Showing the most recent 10 out of 25 publications